ADULT Updated: October 3, 2023

Regimen Reference Order

THOR - nivolumab + gemcitabine + CARBOplatin (Neo-Adjuvant)

ARIA: LUNG - [nivo + gem + CARBO (neoadj)]

Planned Course: Every 21 days for 3 cycles

Indication for Use: Non-Small Cell Lung Cancer Squamous Cell, Resectable; Neo-Adjuvant

Drug Alert: Immune Checkpoint Inhibitor (nivolumab)

CVAD: At Provider's Discretion

Proceed with treatment if:

Day 1

• ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

- AST/ALT equal to or less than 3 times the upper limit of normal
- Total bilirubin equal to or less than 1.5 times the upper limit of normal
- Creatinine clearance is equal to or greater than 30 mL/minute

Day 8

- ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$
 - ❖ DO NOT DELAY OR CANCEL THERAPY WITHOUT CONSULTING MEDICAL ONCOLOGIST

SEQUENCE OF MEDICATION ADMINISTRATION

	Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline			
Not Applicable					

Treatment Regimen THOR – nivolumab + gemcitabine + CARBOplatin (Neo-Adjuvant)

Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
Day 1				
nivolumab	4.5 mg/kg	IV in normal saline 100 mL over 30 minutes Use 0.2 or 0.22 micron filter		
aprepitant	125 mg	Orally 1 hour pre-chemotherapy		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy		
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy		
gemcitabine	1000 mg/m ²	IV in normal saline 250 mL over 30 minutes		



CARBOplatin	AUC 6 mg/mL.min; maximum dose 900 mg (see table below)	IV in D5W 250 mL over 30 minutes		
Day 8				
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy		
gemcitabine	1000 mg/m ²	IV in normal saline 250 mL over 30 minutes		
Maximum nivoluma All doses will be auto more information	· ·	vithin CCMB Approved Dose Bands. See Dose Banding document for		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin, glucose and TSH as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after nivolumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Day 8

CBC

Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline		
aprepitant	80 mg	Orally once daily on Days 2 and 3		
dexamethasone	8 mg	Orally once daily on Days 2 and 3		
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting		


DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- · Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
 - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy



ADDITIONAL INFORMATION

- nivolumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated
- Thoracic Surgeon will order and assess morning cortisol and TSH pre-operative to assess for preoperative immunerelated endocrinopathies
- CARBOplatin dosing considerations:
 - o CCMB Thoracic DSG uses actual body weight to calculate GFR
 - CCMB Thoracic DSG uses a maximum CARBOplatin dose of 900 mg for this regimen
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber



AUC = Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure).

